Evidence map›Paper›PMID 36367677›Full record

ArticleInfectious diseases and therapy2023

Societal Preferences for Meningococcal B Vaccination in Children: A Discrete Choice Experiment in Spain.

Federico Martinón-Torres, Ángel Gil de Miguel, Jesús Ruiz-Contreras, Laura A Vallejo-Aparicio, Andrea García, María C Gonzalez-Inchausti, Eduardo de Gomensoro, Zeki Kocaata, Clara Gabás-Rivera, Marta Comellas and 2 more

Open access · goldAbstract read
In one paragraph

Article in Infectious diseases and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Observational
  5. Article
  6. Article
  7. An effective vaccine is only the first step: the need to create and sustain demand for TB vaccines.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 2 countries.

Federico Martinón-TorresTranslational Pediatrics and Infectious Diseases, Pediatrics Department, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain.ORCID http://orcid.org/0000-0002-9023-581X
Ángel Gil de MiguelDepartment of Preventive Medicine and Public Health, Universidad Rey Juan Carlos, Madrid, Spain.
Jesús Ruiz-ContrerasDepartment of Pediatrics, Hospital Universitario 12 de Octubre, Madrid, Spain.
Laura A Vallejo-AparicioGSK, Madrid, Spain. laura.a.vallejo@gsk.com.
Andrea GarcíaGSK, Madrid, Spain.
María C Gonzalez-InchaustiGSK, Madrid, Spain.
Eduardo de GomensoroGSK, Madrid, Spain.
Zeki KocaataGSK, Wavre, Belgium.
Clara Gabás-RiveraOutcomes'10, Castellón, Spain.
Marta ComellasOutcomes'10, Castellón, Spain.
Miriam PradesOutcomes'10, Castellón, Spain.
Luis LizánOutcomes'10, Castellón, Spain.
GlaxoSmithKline (Spain) · ESConsorcio Hospitalario Provincial de Castellón · ESGlaxoSmithKline (Belgium) · BEUniversidad Complutense de Madrid · ESUniversidade de Santiago de Compostela · ESUniversidad Rey Juan Carlos · ESUniversitat Jaume I · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionImmunization is the most effective strategy for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B (MenB); however, parents need to weigh the risk-benefit and financial impact of immunizing their children against MenB in the absence of a national immunization program (NIP). This study aimed to explore societal preferences (of parents and pediatricians) regarding the attributes of a MenB vaccine in Spain.

methodsA discrete choice experiment (DCE) based on cross-sectional surveys was carried out to determine preferences. A literature review and scientific committee determined the six attributes related to the MenB vaccine included in the DCE: vaccination age, cost, duration, percentage of protection, adverse events probability, and expert/authority recommendation. Data were analyzed using a mixed logit model. Relative importance (RI) of attributes was calculated and compared between parents and pediatricians.

resultsA total of 278 parents [55.8% female, mean age 40.4 (standard deviation, SD 7.3) years] and 200 pediatricians [73.0% female, mean age 45.8 (SD 12.9) years] answered the DCE. For parents, the highest RI was attributed to vaccine cost, expert/authority recommendation, and percentage of protection (26.4%, 26.1%, and 22.9%, respectively), while for pediatricians the highest RI was assigned to percentage of protection, expert/authority recommendation, and vaccination age (27.2%, 23.7%, and 22.6%, respectively). Significant differences between parents and pediatricians were found in the RI assigned to all attributes (p < 0.001), except for vaccine recommendation.

conclusionIn the decision regarding MenB vaccination, cost was a driver in parental decision-making but had a low RI for pediatricians and, conversely, vaccination age was highly valued by pediatricians but was the attribute with least importance for parents. Despite these differences, expert/authority recommendation and percentage of protection were essential criteria for both groups. These results provide relevant information about MenB vaccination, highlighting the importance of considering societal preferences for NIP inclusion.

Indexed as

ChildrenDiscrete-choice experimentMeningococcal diseaseMeningococcus BNeisseria meningitidisPediatricPreferencesSerogroup BVaccinationVaccine

Identifiers

PMID36367677
PMCPMC9868201
OpenAlexW4308766521

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.